GlassScriptPhysician profile
Ashley T Davis
NPI 1124538780
$5,295.06
in general payments reported to CMS, 2019-2025
24 companies · $37.86 in 2025
The $37.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,734 · 2022: $1,502 · 2023: $973 · 2024: $48.67 · 2025: $37.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Travel and Lodging: $201 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.20 |
| Travel and Lodging | $200.79 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.33 | 2021-2023 | |
| Amgen INC. | $745.95 | 2021-2025 | Amjevita, Otezla, Enbrel |
| Janssen Biotech, INC. | $617.04 | 2021-2023 | Simponi Aria, Simponi, Stelara |
| Ucb, INC. | $515.15 | 2021-2023 | Cimzia |
| Pfizer INC. | $301.37 | 2021-2023 | |
| Lilly USA, LLC | $212.04 | 2021 | |
| Glaxosmithkline, LLC. | $208.26 | 2021-2023 | Benlysta |
| Depuy Synthes Sales INC. | $200.79 | 2023 | |
| Novartis Pharmaceuticals Corporation | $131.00 | 2022-2023 | |
| Seagen INC. | $125.14 | 2023 | Tukysa |
| Aurinia Pharma U.S., INC. | $109.47 | 2021-2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $85.78 | 2022-2025 | Cuvitru, Ninlaro |
| Horizon Therapeutics Plc | $77.96 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $67.71 | 2021-2022 | |
| Genzyme Corporation | $51.53 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.76 | 2021-2022 | |
| Sobi, INC | $47.59 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $40.26 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $31.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.47 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.45 | 2021-2022 | |
| Secura Bio, INC. | $17.33 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.79 | 2023 | Purified Cortrophin Gel |
| Abbott Laboratories | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.